Neurogene (NGNE) Q2 2026 earnings summary

Executive summary

• Completed dosing in the Embolden registrational trial for NGN-401 in Rett syndrome; topline results expected in H2 2027.

• Announced positive long-term Phase 1/2 data for NGN-401, with all participants showing developmental milestone gains, no milestone loss, and favorable safety at 1E15 vg dose.

• NGN-401 received Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease, and PRIME designations from FDA, EMA, and UK MHRA, expediting regulatory pathways.

• Initiated PPQ campaign in July 2026 to support BLA submission for NGN-401, with completion expected by year-end 2026.

• Discontinued NGN-101 Batten disease program after FDA denied RMAT designation; evaluating options for the asset.

Financial highlights

• Net loss of $34.5M for Q2 2026 and $65.4M for the six months ended June 30, 2026, compared to $22.0M and $44.7M in the prior year periods.

• Research and development expenses rose to $25.5M for Q2 2026 (up $6.1M YoY) and $50.6M for the six months (up $13.5M YoY), mainly due to NGN-401 clinical trial and manufacturing costs.

• General and administrative expenses increased to $11.2M for Q2 2026 (up $4.5M YoY) and $19.4M for the six months (up $4.5M YoY), mainly due to higher stock-based compensation and headcount.

• Cash, cash equivalents, and short-term investments totaled $225.4M as of June 30, 2026; after July 2026 public offering, pro forma balance is $360.2M, funding operations into Q1 2029.

• Oversubscribed public offering raised $144M in gross proceeds in July 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into Q1 2029.

• Topline data from Embolden trial anticipated in H2 2027; no interim updates planned.

• Completion of BLA-enabling PPQ runs expected by year-end 2026.

• Ongoing investment in NGN-401 clinical development, pre-commercial activities, and early-stage pipeline leveraging EXACT platform.